

# Compression Quality Affects Heart Attack Survival

BY SHERRY BOSCHERT  
San Francisco Bureau

SAN FRANCISCO — The timing of chest compressions in CPR can mean life or death to some patients in cardiac arrest, Lance B. Becker, M.D., said at the annual meeting of the American College of Emergency Physicians.

An observational study of approximately 100 patients being resuscitated in a hospital counted the number and measured the rate of chest compressions through a personal digital assistant operated by a nurse at the rescue scene.

Even in this small group of patients, those who received the 80-100 chest compressions per minute during CPR recommended by the American Heart Association were significantly more likely to survive, compared with those who received lower compression rates, said Dr. Becker, director of the emergency resuscitation center and professor of emergency medicine at the University of Chicago.

The study will be published in the Feb. 1, 2005, issue of the journal *Circulation*, he said.

The results especially are cause for concern when combined with new concepts about three phases of cardiac resuscitation, Dr. Becker added. He and others have proposed that the first, "electrical" phase of ventricular fibrillation is well treated by defibrillation, but patients in a second, "circulatory" phase may be better treated by first receiving compression, then

**'It has to be good compression. I'm worried about this. I think there are really good data that [show] we're not doing a great job on cardiac compression.'**

defibrillation. In a third, "metabolic" phase, newer therapies are needed in addition to compression and defibrillation to save more lives, he said. At present, all patients in ventricular fibrillation undergo defibrillation.

"In that second phase, compression is important, but it has to be good compression," Dr. Becker explained. "I'm worried about this. I think there are really good data that [show] we're not doing a great job on cardiac compression."

A randomized, controlled trial in 2003 compared standard defibrillation with CPR first, then defibrillation in approximately 200 patients being resuscitated after cardiac arrest outside of hospitals. In a subgroup of patients reached by rescuers more than 5 minutes after cardiac arrest (who could be considered to be in that second phase of ventricular fibrillation), 20% who underwent compression plus defibrillation remained alive 1 year later, compared with 4% in the defibrillation-only group (*JAMA* 2003;289:1389-95).

Animal studies back this concept, Dr. Becker said.

Physicians can begin today to save more lives by insisting that CPR be done appropriately, he suggested.

Dr. Becker and his associates are studying a new device to give resuscitators instant feedback on how well they're doing CPR. An accelerometer and a pressure gauge embedded into a sternal pad placed on the patient's chest are wired to a defibrillator and attached to a minicomputer.

The device accurately measures the timing of compressions down to the mil-

lisecond and gives a good measurement of the depth of each compression, among other data.

In some patients, the readings show faster ventilation than compression. Hyperventilation in someone who has almost no cardiac output can increase venous return and cause what others have termed "death by ventilation," Dr. Becker noted.

The investigational device can talk to rescuers with messages such as, "Slow

down your ventilation," or "Speed up your compression."

It is being studied in U.S. hospitals and on patients arresting outside of hospitals in Europe to see if it improves CPR and, thus, survival.

Early results seem "very promising," Dr. Becker said.

He has financial relationships with a series of companies involved in developing the device and is a paid consultant to two of them. ■

## SAVE THE DATE

### Ob.Gyn. News® & Family Practice News®

AND

### Boston University School of Medicine

JOINTLY SPONSOR



## A Practical Update in Sexually Transmitted Infections: Advances in Diagnosis and Treatment

A Continuing Medical Education Conference designed for all health care professionals involved in women's health.

APRIL 9-10, 2005

Willard InterContinental Washington Hotel, Washington, D.C.

### Topic Highlights

Lower Genital Tract Infections

Genital Herpes, Chlamydia, and Gonorrhea

Human Papillomavirus Vaccine Update

Pelvic Inflammatory Disease

Cervical Cancer Screening

The Enigma of Chorioamnionitis

Human Papillomavirus Update

Sexually Transmitted Infections in Adolescents

Role of Infections in Pre-Term Labor

Urinary Tract Infections

**Accreditation:** This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and *Ob.Gyn. News* and *Family Practice News*. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of 10.25 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Cognate hours have been applied for through the American College of Obstetricians and Gynecologists.

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.

Participants may earn up to 10.9 nursing CE credits.

### To register, please contact:

Department of Continuing Medical Education  
Boston University School of Medicine  
715 Albany Street, A305  
Boston, MA 02118-2526  
Telephone: (617) 638-4605  
FAX: (617) 638-4905

### Tuition:

Physicians-\$325  
Residents and Nurses-\$225

### Check our web sites for program updates:

<http://www.bu.edu/eme>,  
[www.obgynnews.com](http://www.obgynnews.com), or  
[www.efamilypracticenews.com](http://www.efamilypracticenews.com)

### Reserve your rooms NOW:

Willard InterContinental Washington  
(202) 628-9100  
Mention the *Ob.Gyn. News/Family Practice News/Boston University School of Medicine* Group to receive the special rate of \$239 per night.

### Course Directors

Jack D. Sobel, MD  
Wayne State University, Detroit  
Phillip G. Stubblefield, MD  
Boston University School of Medicine  
Jonathan M. Zenilman, MD  
Johns Hopkins School of Medicine, Baltimore

### Faculty

Patricia D. Brown, MD  
David A. Eschenbach, MD  
Ronald S. Gibbs, MD  
Patti E. Gravitt, MS, PhD  
Jennifer Gunter, MD  
Anne M. Rompalo, MD  
Jane R. Schwebke, MD  
David E. Soper, MD

### Educational Needs

The results of laboratory and clinical studies in recent years have changed our understanding of the nature of some STIs. Advances in techniques to diagnose and therapeutic methods to treat STIs have evolved rapidly as have standards of care. What has not changed is the adverse impact that many of these infections can have on the lives of women, their sexual partners, and, in many cases, their pregnancies. It is important that women's health specialists remain up to date on advances and current recommendations in the treatment of STIs.

### Educational Objectives

At the conclusion of this meeting, participants will be able to:

- Discuss what is currently known about the etiology and diagnosis of lower genital tract infections, and how this information has effected changes in the treatment of trichomoniasis, candidiasis, and bacterial vaginosis.
- Explain the role of the women's health care provider in screening for and treating genital herpes, chlamydia, gonorrhea, and pelvic inflammatory disease.
- Articulate what is currently known about the nature, diagnosis, and treatment of human papillomavirus (HPV) infections, including vaccine development and the management of genital warts.
- Outline the management of STIs in special populations of women, including adolescents, pregnant women, and HIV-infected patients.
- Describe recent findings regarding urinary tract infections, Group B strep, and best practices for detection and treatment of pre-malignant lesions.

This conference is supported in part with an educational grant from 3M Pharmaceuticals, Quidel Corporation and Presutti Laboratories.